

Docket No. 126625.00801
Serial No. 10/763,309
Filing Date: January 23, 2004
Paper Dated: June 21, 2007

CLAIMS

What is Claimed:

1. (Original) A composition comprising citrulline and an Hmg-CoA reductase inhibitor.
2. (Original) The composition of claim 1, wherein said citrulline is L-citrulline.
3. (Original) The composition of claim 1, wherein said citrulline is a salt of L-citrulline.
4. (Original) The composition of claim 1, wherein said citrulline is L-citrulline hydrochloride.
5. (Original) The composition of claim 1, wherein the Hmg-CoA reductase inhibitor is pravastatin.
6. (Original) The composition of claim 1, wherein the Hmg-CoA reductase inhibitor is selected from the group consisting of atorvastatin, cerivastatin, simvastatin, lovastatin, compactin, fluvastatin, mevastatin, fluindostatin, velostatin and dalcavastatin.
7. (canceled)
8. (Currently amended) The composition of claim 1, further comprising a pharmaceutically acceptable carrier.
9. (Currently amended) The composition of claim 1, wherein the composition is formulated ~~in~~ for a form of administration selected from the group consisting of intravenous, buccal, intracoronary, intra-arterial, intrapericardial, intramuscular, topical, intranasal, rectal, sublingual, oral, subcutaneous, patch and inhalation.

Docket No. 126625.00801
Serial No. 10/763,309
Filing Date: January 23,2004
Paper Dated: June 21, 2007

10. (Currently amended) A therapeutic composition comprising a therapeutically effective amount of citrulline, and an Hmg-CoA reductase inhibitor and a pharmaceutically acceptable carrier.

11. (Original) The composition of claim 10, wherein said citrulline is L-citrulline.

12. (Original) The composition of claim 10, wherein said citrulline is a salt of L-citrulline.

13. (Original) The composition of claim 10, wherein said citrulline is L-citrulline hydrochloride.

14. (Original) The composition of claim 10, wherein the Hmg-CoA reductase inhibitor is pravastatin.

15. (Original) The composition of claim 10, wherein the Hmg-CoA reductase inhibitor is selected from the group consisting of atorvastatin, cerivastatin, simvastatin, lovastatin, compactin, fluvastatin, mevastatin, fluindostatin, velostatin and dalcavastatin.

16. (Canceled)

17. (Currently amended) The composition of claim 10, wherein the composition is formulated ~~in~~ for a form of administration selected from the group consisting of intravenous, buccal, intracoronary, intra-arterial, intrapericardial, intramuscular, topical, intranasal, rectal, sublingual, oral, subcutaneous, patch and inhalation.

18. (Currently amended) A method of treating a subject in need thereof comprising administering a composition comprising citrulline and an Hmg-CoA reductase inhibitor, wherein the level of nitric oxide in said subject is increased.

19. (Original) The method of claim 18, wherein the Hmg-CoA reductase inhibitor enhances nitric oxide synthase activity.

20. (Original) The method of claim 18, wherein said citrulline is L-citrulline.

Docket No. 126625.00801
Serial No. 10/763,309
Filing Date: January 23,2004
Paper Dated: June 21, 2007

21. (Original) The method of claim 18, wherein said citrulline is a salt of L-citrulline.

22. (Original) The method of claim 18, wherein said citrulline is L-citrulline hydrochloride.

23. (Original) The method of claim 18, wherein the Hmg-CoA reductase inhibitor is pravastatin.

24. (Original) The method of claim 18, wherein the Hmg-CoA reductase inhibitor is selected from the group consisting of atorvastatin, cerivastatin, simvastatin, lovastatin, compactin, fluvastatin, mevastatin, fluindostatin, velostatin and dalvastatin.

25. (Currently amended) The method of claim 18, wherein the composition further comprises a pharmaceutically acceptable carrier.

26. (Original) A method of stimulating nitric oxide synthase comprising: administering citrulline and an agonist of nitric oxide synthase.

27. (Original) The method of claim 26, wherein said citrulline is in excess to said agonist.

28. (Original) The method of claim 26, wherein a therapeutically effective amount of said citrulline is combined with a therapeutically effective amount of an Hmg-CoA reductase inhibitor prior to said administration.

29. (Currently amended) The method of claim 28 29, wherein the Hmg-CoA reductase inhibitor is pravastatin.

30. (Currently amended) The method of claim 28 29, wherein the Hmg-CoA reductase inhibitor is selected from the group consisting of atorvastatin, cerivastatin, simvastatin, lovastatin, compactin, fluvastatin, mevastatin, fluindostatin, velostatin and dalvastatin.

Docket No. 126625.00801
Serial No. 10/763,309
Filing Date: January 23, 2004
Paper Dated: June 21, 2007

31. (New) The method of claim 18, wherein said Hmg-CoA reductase inhibitor enhances nitric oxide production.

32. (New) The method of claim 26, wherein said Hmg-CoA reductase inhibitor enhances nitric oxide production.